MX2021008748A - Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias. - Google Patents

Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.

Info

Publication number
MX2021008748A
MX2021008748A MX2021008748A MX2021008748A MX2021008748A MX 2021008748 A MX2021008748 A MX 2021008748A MX 2021008748 A MX2021008748 A MX 2021008748A MX 2021008748 A MX2021008748 A MX 2021008748A MX 2021008748 A MX2021008748 A MX 2021008748A
Authority
MX
Mexico
Prior art keywords
treatment
amino acid
acid derivatives
inflammatory diseases
compounds
Prior art date
Application number
MX2021008748A
Other languages
English (en)
Inventor
Chao Jin
Daniel Paris
Michael Mullan
Original Assignee
The Roskamp Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Roskamp Inst filed Critical The Roskamp Inst
Publication of MX2021008748A publication Critical patent/MX2021008748A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción proporciona ciertos derivados de aminoácidos que inhiben la activación de NF-kB y, por lo tanto, son útiles para el tratamiento de enfermedades inflamatorias. También se proporcionan composiciones farmacéuticas que contienen estos compuestos y procesos para preparar estos compuestos.
MX2021008748A 2019-01-22 2020-01-22 Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias. MX2021008748A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795549P 2019-01-22 2019-01-22
US201962871951P 2019-07-09 2019-07-09
PCT/US2020/014636 WO2020154420A2 (en) 2019-01-22 2020-01-22 Amino acid derivatives for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2021008748A true MX2021008748A (es) 2022-01-24

Family

ID=69726748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008748A MX2021008748A (es) 2019-01-22 2020-01-22 Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.

Country Status (17)

Country Link
US (1) US20220081415A1 (es)
EP (1) EP3924349A2 (es)
JP (1) JP2022524571A (es)
KR (1) KR20210141930A (es)
CN (1) CN113614074A (es)
AU (1) AU2020211980A1 (es)
BR (1) BR112021014372A2 (es)
CA (1) CA3127246A1 (es)
CL (1) CL2021001944A1 (es)
CO (1) CO2021010931A2 (es)
EC (1) ECSP21062210A (es)
IL (1) IL284980A (es)
MA (1) MA54940A (es)
MX (1) MX2021008748A (es)
SG (1) SG11202107977TA (es)
WO (1) WO2020154420A2 (es)
ZA (1) ZA202105229B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6218390B1 (en) * 1998-12-17 2001-04-17 Synaptic Pharmaceutical Corporation Morpholinone and morpholine derivatives and uses thereof
CA2759863A1 (en) * 2009-05-01 2010-11-04 Profectus Biosciences, Inc. Benzamide and naphthamide derivatives inhibiting nuclear factor- kappa (b) - (nf-kb)

Also Published As

Publication number Publication date
US20220081415A1 (en) 2022-03-17
ECSP21062210A (es) 2022-06-30
EP3924349A2 (en) 2021-12-22
BR112021014372A2 (pt) 2021-09-28
WO2020154420A3 (en) 2020-09-10
WO2020154420A2 (en) 2020-07-30
CL2021001944A1 (es) 2022-05-06
SG11202107977TA (en) 2021-08-30
IL284980A (en) 2021-09-30
AU2020211980A1 (en) 2021-08-19
CN113614074A (zh) 2021-11-05
CA3127246A1 (en) 2020-07-30
CO2021010931A2 (es) 2022-01-17
JP2022524571A (ja) 2022-05-09
WO2020154420A4 (en) 2020-11-12
KR20210141930A (ko) 2021-11-23
ZA202105229B (en) 2022-12-21
MA54940A (fr) 2021-12-22

Similar Documents

Publication Publication Date Title
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2023002507A (es) Inhibidores de cd73.
EP3693369A3 (en) Bromodomain inhibitors
NZ788133A (en) Cd73 inhibitors
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
WO2021100029A3 (en) Prodrugs of fulvestrant
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2022016357A (es) Derivados de tetrazol como inhibidores de trpa1.
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
MX2021008748A (es) Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.
ZA202100955B (en) Thrombin inhibitors, formulations, and uses thereof
CR20220668A (es) Derivados de tetrazol como inhibidores de trpa1
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.
WO2018067638A3 (en) High mobility group b1 protein inhibitors
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.